IONS IONIS PHARMACEUTICALS INC

Nasdaq Pharmaceutical Preparations CA CIK: 0000874015
AI RATING
SELL
72% Confidence

Investment Thesis

Ionis demonstrates strong revenue growth of 33.8% YoY, indicating market traction; however, severe negative free cash flow of -$814.6M (3.3x annual revenue burn rate) combined with unprofitable operations and high leverage (3.69x debt-to-equity) create unsustainable financial deterioration. The company's ability to fund operations and service debt is increasingly at risk without near-term profitability inflection.

Strengths

  • + Strong revenue growth of 33.8% YoY showing market demand
  • + Excellent short-term liquidity with 4.10x current ratio and 4.09x quick ratio
  • + Substantial asset base of $3.4B indicating established operations and pipeline

Risks

  • ! Catastrophic negative free cash flow of -$814.6M annually, burning cash at 3.3x revenue rate
  • ! High financial leverage at 3.69x debt-to-equity with $1.8B long-term debt and limited cash cushion of only $173.4M
  • ! Severe operating losses with -47.7% operating margin and -37.6% net margin, indicating core business is unprofitable

Key Metrics to Watch

Financial Metrics

Revenue
246.1M
Net Income
-92.5M
EPS (Diluted)
$-0.56
Free Cash Flow
-814.6M
Total Assets
3.4B
Cash
173.4M

Profitability Ratios

Gross Margin N/A
Operating Margin -47.7%
Net Margin -37.6%
ROE -18.8%
ROA -2.7%
FCF Margin -331.0%

Balance Sheet & Liquidity

Current Ratio
4.10x
Quick Ratio
4.09x
Debt/Equity
3.69x
Debt/Assets
85.8%
Interest Coverage
-22.76x
Long-term Debt
1.8B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T15:28:16.877173 | Data as of: 2026-03-31 | Powered by Claude AI